S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:PRTA

Prothena Stock Forecast, Price & News

$46.59
-3.08 (-6.20%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$45.28
$50.35
50-Day Range
$46.59
$77.39
52-Week Range
$10.72
$79.75
Volume
420,267 shs
Average Volume
416,221 shs
Market Capitalization
$2.17 billion
P/E Ratio
45.23
Dividend Yield
N/A
Beta
1.24
30 days | 90 days | 365 days | Advanced Chart
Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.


Prothena logo

About Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
66
Year Founded
N/A

Sales & Book Value

Annual Sales
$850 thousand
Book Value
$10.53 per share

Profitability

Net Income
$-111.14 million
Pretax Margin
37.37%

Debt

Price-To-Earnings

Miscellaneous

Free Float
32,429,000
Market Cap
$2.17 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/10/2022

MarketRank

Overall MarketRank

2.68 out of 5 stars

Medical Sector

58th out of 1,390 stocks

Pharmaceutical Preparations Industry

20th out of 668 stocks

Analyst Opinion: 4.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Prothena (NASDAQ:PRTA) Frequently Asked Questions

Is Prothena a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Prothena stock.
View analyst ratings for Prothena
or view top-rated stocks.

How has Prothena's stock price been impacted by Coronavirus (COVID-19)?

Prothena's stock was trading at $9.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PRTA shares have increased by 379.3% and is now trading at $46.59.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Prothena?

Prothena saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 1,880,000 shares, an increase of 27.0% from the October 14th total of 1,480,000 shares. Based on an average daily volume of 344,000 shares, the days-to-cover ratio is presently 5.5 days.
View Prothena's Short Interest
.

When is Prothena's next earnings date?

Prothena is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Prothena
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported $2.13 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $2.25 by $0.12. The biotechnology company had revenue of $139.17 million for the quarter, compared to analyst estimates of $140.08 million. Prothena had a trailing twelve-month return on equity of 23.20% and a net margin of 34.76%. During the same quarter in the previous year, the firm posted ($0.77) earnings per share.
View Prothena's earnings history
.

What price target have analysts set for PRTA?

10 Wall Street analysts have issued 12 month target prices for Prothena's stock. Their forecasts range from $14.00 to $103.00. On average, they anticipate Prothena's share price to reach $67.50 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price.
View analysts' price targets for Prothena
or view top-rated stocks among Wall Street analysts.

Who are Prothena's key executives?

Prothena's management team includes the following people:
  • Gene G. Kinney, President, Chief Executive Officer & Director
  • Brandon S. Smith, Chief Operating Officer
  • Tran B. Nguyen, Chief Financial & Strategy Officer
  • Wagner M. Zago, Chief Scientific Officer
  • Hideki Garren, Chief Medical Officer

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.53%), Dimensional Fund Advisors LP (3.39%), Rock Springs Capital Management LP (1.52%), Geode Capital Management LLC (1.33%), Two Sigma Advisers LP (1.02%) and Invesco Ltd. (0.75%). Company insiders that own Prothena stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Karin L Walker, Michael J Malecek and Wagner M Zago.
View institutional ownership trends for Prothena
.

Which institutional investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Prosight Management LP, Pinnacle Associates Ltd., Royal Bank of Canada, Platinum Investment Management Ltd., EAM Investors LLC, EAM Global Investors LLC, and Citadel Advisors LLC. Company insiders that have sold Prothena company stock in the last year include Carol D Karp, Christopher S Henney, Dennis J Selkoe, Karin L Walker, Michael J Malecek, and Wagner M Zago.
View insider buying and selling activity for Prothena
or view top insider-selling stocks.

Which institutional investors are buying Prothena stock?

PRTA stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, SG Americas Securities LLC, BlackRock Inc., UBS Group AG, Marshall Wace LLP, Geode Capital Management LLC, Voloridge Investment Management LLC, and Invesco Ltd..
View insider buying and selling activity for Prothena
or or view top insider-buying stocks.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $46.59.

How much money does Prothena make?

Prothena has a market capitalization of $2.17 billion and generates $850 thousand in revenue each year. The biotechnology company earns $-111.14 million in net income (profit) each year or $1.03 on an earnings per share basis.

How many employees does Prothena have?

Prothena employs 66 workers across the globe.

What is Prothena's official website?

The official website for Prothena is www.prothena.com.

Where are Prothena's headquarters?

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company can be reached via phone at (531) 236-2500, via email at [email protected], or via fax at 353-1902-3510.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.